Target intelligence / Profile preview

Ubiquitin-like with PHD and RING finger domains 2 (UHRF2)

Target
UHRF2
Molecular classification
Enzyme: E3 ubiquitin ligase, Histone modification, Nuclear protein
01

Overview

Ubiquitin-like with PHD and RING finger domains 2 (UHRF2) is a nuclear protein and E3 ubiquitin ligase involved in cell-cycle regulation, DNA methylation, histone modification, and DNA repair. It contains multiple functional domains including a PHD finger, SRA (SET and RING-associated) domain, and a RING finger domain. UHRF2 can ubiquitinate specific substrates (such as PCNP, cyclins, and p21) and plays roles in the maintenance of genomic stability, cell-cycle progression, and may contribute to tumorigenesis. It also participates in intranuclear degradation of polyglutamine aggregates and is implicated in cellular response to DNA damage.

Other names
UHRF2RNF107NIRFTDRD23URF2Ubiquitin-Like With PHD And RING Finger Domains 2, E3 Ubiquitin Protein LigaseRING-Type E3 Ubiquitin Transferase UHRF2E3 Ubiquitin-Protein Ligase UHRF2Np95-Like RING Finger ProteinRING Finger Protein 107Nuclear Protein 97MGC33463Nuclear Zinc Finger Protein NP97EC 2.3.2.27EC 6.3.2
02

Mechanism of action

Modulation of cell cycle checkpoint regulation; Induction of cell cycle arrest (through ubiquitination of cyclins); Alteration of DNA methylation and histone modification; Promotion or inhibition of protein degradation via the proteasome

03

Biological functions

Cell cycle regulationDNA methylationHistone modificationDNA repairUbiquitinationCell proliferationTumorigenesis
04

Disease associations

Cancer (tumorigenesis)Potential implications in neurodegenerative disease (intranuclear degradation of polyglutamine aggregates)Other roles may be possible due to functions in DNA repair and cell cycle regulation
05

Safety considerations

Targeting E3 ubiquitin ligases generally raises concerns for off-target and pleiotropic effects, as these enzymes regulate multiple cellular substratesTherapeutic manipulation could lead to dysregulation of cell cycle or DNA repair, resulting in cytotoxicity, genomic instability, or unwanted cell deathOther safety challenges typical for drugs involving cell-cycle regulators
06

Biomarkers

No specific validated biomarkers for patient selection or efficacy monitoring directly cited for UHRF2. Its expression or activity may be associated with cell proliferation and tumorigenesis and could potentially serve as a cancer biomarker in some contexts.

Beyond the preview

Go deeper on Ubiquitin-like with PHD and RING finger domains 2 (UHRF2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ubiquitin-like with PHD and RING finger domains 2 (UHRF2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call